TP63 and neoplasm: However, in the second cohort where p63 was inactivated (sgTP63#4), we identified largely p63-negative tumors at endpoint, allowing us to interrogate the tumor microenvironment in a loss of function context (Figure 4D–E and Figure 4—figure supplement 1B).